← All stocks

Voyager Therapeutics, Inc.

VYGR Net selling

CIK 0001640266 #3912 in the set updated 17 Sep 2026

Bought (12 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$334.60K

$257.35K on a plan · $0.00 straight out of an exercise

Sold at will

$77.25K

3 of 12 sales

Net

−$334.60K

−$77.25K against sales at will

By person

7 insiders · 12 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Sandrock Alfred

President and CEO

—

$184.45K (4) scheduled

−$184.45K

472,549

0.7669%

$1.83M

+43.1%

Swartz Robin

COO & CBO

—

$55.29K (3) scheduled

−$55.29K

199,738

0.3242%

$772.99K

+68.1%

Jorgensen Nathan D.

Chief Financial Officer

—

$54.24K (2) scheduled

−$54.24K

151,416

0.2457%

$585.98K

—

Carter Todd Alfred

Chief Scientific Officer

—

$40.62K (3) scheduled

−$40.62K

145,718

0.2365%

$563.93K

+66.3%

Ferguson Toby

Chief Medical Officer

—

183,914

0.2985%

$711.75K

+75.2%

Fahey Sandell Jacquelyn

Chief Legal Officer

—

123,143

0.1998%

$476.56K

+33.9%

Shiferman Gregory L.

SVP and General Counsel

—

50,000

0.0811%

$193.50K

—

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 28

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 9

Sales straight out of an exercise 0

Sales at will 3

Transactions with no price 0

Shares from compensation/vesting 291,500

History held since 21 Dec 2016